effort refocu product innov vs busi model innov allow
acceler sale growth begin next year albeit modest initi increas
momentum beyond geoff martha take helm ceo expect
focu product innov continu like commentari earn
call becom aggress tuck-in decis
capit alloc highest growth segment increas weighted-
averag market growth rate wamgr say right thing
importantli think right thing well
share current trade discount med-tech stock
trade ep owe slower top bottom line growth
profil howev growth profil improv expect pe multipl
expand increas price target reflect higher target
pe vs ep pipelin progress marvel etc
strong pipelin product across busi believ sale
growth acceler like come sustain number year
come quarter expect number pipelin mileston medic
confer notabl clinic trial data also host bi-annu
investor confer next year believ provid signific look
hood show engin begin rev
potenti turn back growth mode also
good cash flow profil well help fuel grow biggest pushback
anticip view disappoint past rel
valuat think risk/reward favor
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid high-
single-digit ep growth believ stock
valuat attract expect stock pe
appreci sale growth improv
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
sale street expect constant currenc
organ ep streets/our estim rel
estim function higher sales/slightli better op margin
lower-than-expect interest expens tax rate rais
full year ep guidanc rang beat maintain organ growth
guidanc increas cvg mitg ritg growth off-set reduct
diabet growth expect maintain overweight rate view base
longer term outlook turn pipelin stock valuat
opportun improv cash flow deploy valu enhanc
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
restor therapi group rtg deliv expect constant
currenc growth organ growth strong sale growth spine
organ includ enabl tech like mazor robot brain therapi
off-set slower growth pain therapi
pipelin continu look solid view key program track
emerg market continu grow doubl digit
free cash flow continu strong quarter ytd
cr hf expect factor drive weak
eas quarter ahead tyrx suppli challeng manufactur
move facil resolv mid-singl digit pace growth micra
us growth off-set low doubl digit declin icd due
cobalt icd/crt famili plan launch plu micra av track launch
last tough quarter lvad share loss anniversari
diabet grew reflect declin us increas ou
full year diabet sale outlook lower low-single-digit growth low end
higher growth busi unit cvg mitg rtg
expect off-set full year organ sale growth maintain
gross margin y/i impact relat fx
sale organ constant currenc report basi
adj gross margin y/i manag highlight fx
china tariff drive major impact
sg sale y/i reflect effici improv
result enterpris excel initi
 sale y/i line expect
oper margin y/i larg in-lin expect
adjust tax rate higher year ago y/i
though much expect contribut ep beat
adjust ep y/i ex-fx
expect overal organ growth divis organ basi expect mitg rtg
growth cvg growth diabet expect flat slightli fx expect
headwind manag expect slight improv oper margin off-set currenc headwind ep expect
rang includ estim neg impact fx slightli street pre-releas
maintain organ sale growth guidanc though divis chang cvg
previou mitg previou rtg growth previou diabet grow low
singl digit previou lower end rang fx still expect headwind continu expect
oper margin expand fx neutral ep guidanc rais beat prior ep
includ fx headwind previou
addit takeaway earn call pleas see note
click titl link
first look sale ep beat ep guidanc rais overweight maintain
call note anticip diabet outlook reduc big focu busi off-set
host gener manag call friday see relat weak opportun
note includ commentari marvel micra av data
kstew meet note meet one go
hugo ra expect realli acceler mitg sale growth
kstew note mdt-ra tidbit time impact ce mark us year
model avail barclay live via link
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
